Most Commonly Used ACE Inhibitors with Brand and Generic Names
The most commonly used ACE inhibitors include lisinopril (Prinivil, Zestril), enalapril (Vasotec), ramipril (Altace), and captopril (Capoten), which are widely prescribed for hypertension, heart failure, and diabetic nephropathy. 1
Comprehensive List of ACE Inhibitors
First-Line/Most Commonly Used ACE Inhibitors
Lisinopril
Enalapril
- Brand name: Vasotec
- Dosing: 5-40 mg daily in 1-2 divided doses
- Notable features: Prodrug requiring hepatic activation 1
Ramipril
Captopril
Other Commonly Used ACE Inhibitors
Benazepril
- Brand name: Lotensin
- Dosing: 10-40 mg daily in 1-2 divided doses 1
Fosinopril
Quinapril
- Brand name: Accupril
- Dosing: 10-80 mg daily in 1-2 divided doses 1
Perindopril
- Brand name: Aceon
- Dosing: 4-16 mg daily in 1-2 divided doses 1
Trandolapril
Moexipril
Clinical Considerations
Pharmacokinetic Differences
- Half-life variations: Range from 1 hour (captopril) to over 24 hours (trandolapril) 3
- Bioavailability: Varies widely from 11% (trandolapril) to >60% (captopril) 3
- Elimination routes: Most are primarily eliminated through kidneys, but benazepril, fosinopril, ramipril, and trandolapril also have significant hepatic elimination 3
Important Adverse Effects
- Cough: Occurs in up to 20% of patients, more common in women and Asian patients 1
- Angioedema: Occurs in <1% of patients but more frequent in Black patients; requires permanent discontinuation of all ACE inhibitors 1
- Hyperkalemia: Especially in patients with renal impairment or those taking potassium-sparing diuretics 1
- Acute renal failure: More common in patients with bilateral renal artery stenosis, volume depletion, or heart failure 1
Dosing Considerations
- Renal impairment: Dose adjustment required for most ACE inhibitors when creatinine clearance is <30 mL/min 3
- Heart failure: Start with low doses and titrate gradually 1
- Elderly patients: Consider starting at lower doses 4
ACE inhibitors remain first-line agents for hypertension, heart failure, and diabetic nephropathy due to their proven mortality benefits and generally favorable side effect profile compared to other antihypertensive classes.